Active Ingredient(s): Lutetium Lu-177 Vipivotide Tetraxetan
FDA Approved: * March 23, 2022
Pharm Company: * AAA USA NOVARTIS
Category: Cancer

Lutetium (177Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).[1][2] Lutetium (177Lu) vipivotide tetraxetan is a targeted radioligand therapy.[2][3] The most common adverse reactions include fatigue, dry mouth, nausea, anemia, decreased appetite, and... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Pluvicto 27 mci/Ml Intravenous Injection, Solution
NDC: 69488-010
Advanced Accelerator Applications USA, Inc

Related Brands

Drugs with the same active ingredients